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Background: Information regarding growth hormone (GH) therapy in neonatal patients with methylmalonic acidemia
(MMA) is lacking. We present our experience with GH therapy in neonatal patients with MMA.
Methods: Four neonatal patients with mut0 type MMA were identified through newborn screening for elevated propionyl-
carnitine (C3) levels. GH therapy (0.6 IU/kg/week, subcutaneously) was prescribed for patient 1 after 1 month of admis-
sion, and was prescribed for patients 2, 3 and 4 on the 1st day of admission. We evaluated weight, skin erosion, hospital
stay, and serum levels of C3 after GH therapy.
Results: All of the neonatal patients with MMA displayed obvious weight gain and distinct improvement in skin erosions
after GH therapy. The duration of hospital stay for patients 2, 3 and 4 was reduced compared to that of patient 1.
However, the metabolic effects of GH therapy on reducing serum levels of C3 seem to be indeterminate.
Conclusion: Our clinical findings suggest that GH therapy has potentially beneficial effects on neonatal patients with
MMA. [J Chin Med Assoc 2009;72(9):462–467]
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Introduction
Methylmalonic acidemia (MMA) is a rare metabolic
disorder that is inherited as an autosomal recessive
trait, occurring in 1:50,000 to 1:80,000 newborns.1
MMA encompasses a heterogeneous group of disor-
ders that are characterized by impaired metabolism of
methylmalonic acid that is generated during the me-
tabolism of certain amino acids (isoleucine, methion-
ine, threonine, and valine), odd-chain fatty acids and
cholesterol.2 These disorders are due to a deficiency
of the adenosylcobalamin-dependent enzyme methyl-
malonyl-CoA mutase (MCM, EC 5.4.99.2) or a defect
in cobalamin metabolism.2 At least 8 different comple-
mentation groups (mut0, mut–, cblA, cblB, cblC, cblD,
cblF, and cblH) cause MMA.3 Patients with the mut0
defect have undetectable MCM activity, and typically
present during the newborn period.4 Most of these
patients with mut0 type of MMA may die early, before
a diagnosis can be made, and those who survive often
have a complicated clinical course with significant neu-
rodevelopmental handicap.5 Conventional therapy of
MMA consists of dietary management, which can be
supplemented with special formula that does not 
contain isoleucine, methionine, threonine or valine,
L-carnitine supplementation, and inhibition of intestinal
bacterial propionate production with oral antibiotics.6
Furthermore, successful peritoneal dialysis has been
reported in neonatal MMA patients with hyperam-
monemia,7,8 and hemodialysis is strongly suggested
nowadays.1 However, poor feeding, poor growth, and
intractable skin erosions are common findings in pa-
tients with MMA despite aggressive management with
conventional therapy.9 Growth hormone (GH) therapy
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was shown to be beneficial in growth and metabolic
control in a 4.5-year-old boy9 and in an 11.9-year-old
girl,10 both of whom had mut0 type MMA. However,
GH therapy has never been reported in neonatal pa-
tients with MMA. Therefore, we present our experi-
ence with 4 neonatal MMA (mut0 type) patients who
were managed with conventional and GH therapies,
and clinically evaluate the beneficial effects of GH
therapy in neonatal MMA patients.
Methods
Patient reports
Patient 1
This male neonate was born to healthy non-consan-
guineous Taiwanese parents at 40 weeks of gestation
and weighed 2,920 g. Poor activity with elevated se-
rum levels of propionylcarnitine (C3, 19.18 μM; nor-
mal, < 7 μM) and elevated C3/acetylcarnitine ratio
(C3/C2, 1.18; normal, < 0.25) detected by newborn
screening using tandem mass spectrometry (MS/MS)
were noted at 5 days of age. The patient was then
referred to our hospital for confirmatory testing and
management.
On admission, he was mildly dehydrated and
lethargic. The results of laboratory investigations per-
formed on admission are shown in Table 1. These
laboratory findings demonstrated the presence of leu-
kopenia, anemia, ketotic hypoglycemia, hyperammo-
nemia, metabolic acidosis, and hyperglycinemia, which
were compatible with organic acidemia. Organic acid
analysis of urine demonstrated increased excretion of
methylmalonic acid, leading to the diagnosis of MMA.
The mut MMA phenotype was established by mea-
suring MCM activity in lymphocytes from the patient’s
peripheral blood. MCM activity was undetectable in
the patient’s lymphocytes (< 0.05 nmol/min/mg pro-
tein vs. the normal control value of 3.8 nmol/min/
mg protein), therefore defining a mut0 MMA phe-
notype. Direct sequencing of genomic DNA showed 
G-to-A transition at position 323 (c.323G > A) and
C-to-T transition at position 1741 (c.1741C > T),
respectively.
The patient received conventional therapy (dietary
management, L-carnitine supplementation, and oral
antibiotics) with peritoneal dialysis after admission.
His serum ammonia levels fell (from 475 μg/dL to
37 μg/dL) and metabolic acidosis was corrected (pH,
from 7.29 to 7.44; anion gap, from 20.2 mmol/L to
13.2 mmol/L) in 48 hours. However, the patient had
persistently elevated serum levels of C3 (maximum of
31.70 μM), which failed to respond to conventional
therapy. Furthermore, poor feeding, poor growth (his
weight showed an increase of 142 g in the 1st month
of admission) and skin erosions, which progressively
developed on the face, trunk, buttocks and 4 extrem-
ities, were found during the 1st month of admission
despite aggressive management with conventional
therapy. After 1 month, GH therapy was prescribed.
Subsequently, the patient’s weight showed obvious
increases in the 2nd and 3rd months of admission
(Figure 1). His appetite and skin erosions also gradu-
ally improved after GH therapy.
Patient 2
This female neonate was born to healthy non-consan-
guineous Taiwanese parents at 38 weeks of gestation
and weighed 2,900g. The 1st MS/MS newborn screen-
ing performed at 2 days of age showed elevated se-
rum level of C3 (12.44 μM) and elevated C3/C2 ratio
(0.81). The 2nd MS/MS test performed at 5 days of
age showed a lower serum level of C3 (8.99 μM) and
lower C3/C2 ratio (0.67). However, the 3rd test per-
formed at 7 days of age showed an unusually elevated
serum level of C3 (14.98 μM) and elevated C3/C2
ratio (1.86). The patient was asymptomatic until 8 days
of age, and recurrent vomiting subsequently presented.
MMA was highly suspected, and the patient was im-
mediately referred to our hospital for confirmatory
testing and management.
The results of the laboratory investigations per-
formed on admission are summarized in Table 1, and
mut0 type MMA was the diagnosis. The patient re-
ceived conventional therapy with peritoneal dialysis
after admission. Her serum ammonia levels fell (from
634 μg/dL to 47 μg/dL) and metabolic acidosis was
corrected (pH, from 7.29 to 7.41; anion gap, from
22.4 mmol/L to 13.4 mmol/L) in 45 hours. The dif-
ference in management from that of patient 1 was that
GH therapy was immediately prescribed on admis-
sion, and her weight subsequently showed significant
increases, in contrast to that of patient 1 during the
1st month of admission (Figure 1). Slight skin erosions
were found over the perianal area, but were much
improved after intensive skin care.
Patient 3
This female neonate was born to healthy non-
consanguineous Taiwanese parents at 38 weeks of
gestation and weighed 2,652 g. Shortness of breath
with elevated serum level of C3 (16.65 μM) and ele-
vated C3/C2 ratio (0.58) detected by MS/MS new-
born screening were noted at 3 days of age. She was
referred to our hospital for confirmatory testing and
management.
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On admission, she was dehydrated, lethargic and
showed muscular hypotonia. The results of laboratory
investigations performed on admission are summarized
in Table 1, and mut0 type MMA was the diagnosis.
The patient received conventional therapy with peri-
toneal dialysis after admission. Her serum ammonia
levels fell (from 603 μg/dL to 86 μg/dL) and meta-
bolic acidosis was corrected (pH, from 7.09 to 7.35;
anion gap, from 32.2 mmol/L to 14.2 mmol/L) in
41 hours. GH therapy was immediately prescribed on
admission, and her weight subsequently showed sig-
nificant increases, in contrast to that of patient 1 dur-
ing the 1st month of admission (Figure 1). Slight skin
erosions were found over the perianal area, but were
much improved after intensive skin care.
Patient 4
This male neonate was born to healthy non-consan-
guineous Taiwanese parents at 37 weeks of gestation
and weighed 2,780 g. At 3 days of age, shortness of
breath, poor feeding, and lethargy were noted at the
hospital where he was born. Laboratory tests per-
formed there showed the following: white blood cell
count, 9,500/mm3; hemoglobin, 13.5 g/dL; platelet
count, 330,000/mm3; alanine transaminase, 43 IU/L;
aspartate transaminase, 90 IU/L; blood urea nitrogen,
3.0 mg/dL; creatinine, 0.7 mg/dL; blood glucose,
25mg/dL; serum ammonia, 750μg/dL; arterial blood
gas, pH 7.10; anion gap, 31 mmol/L. These labora-
tory findings were compatible with organic acidemia,
and at that time, elevated serum level of C3 (12.39μM)
Table 1. Patient characteristics and laboratory investigations of the 4 neonatal patients with methylmalonic acidemia (MMA)
Normal values Patient 1 Patient 2 Patient 3 Patient 4
Parents Non- Non- Non- Non-
consanguineous consanguineous consanguineous consanguineous
Sex Male Female Female Male
GA (wk) 40 38 38 37
BW (g) 2,920 2,900 2,652 2,780
Age at onset (d) 5 8 3 3
Chief complaint Poor activity Recurrent Shortness of Shortness of 
vomiting breath breath
Initial C3 (μM) < 7 19.18 12.44 16.65 12.39
Initial C3/C2 < 0.25 1.18 0.81 0.58 0.77
WBC (/mm3) 9,000–35,000 7,000 7,200 3,300 7,400
Hb (g/dL) 15–20 13.8 11.4 13.7 12.9
PLT (/mm3) 250,000–450,000 389,000 318,000 89,000 461,000
ALT (IU) 1–25 20 44 13 34
AST (IU) 35–140 31 13 113 135
BUN (mg/dL) 4–15 16 5 20 13
Cr (mg/dL) < 0.6 0.1 0.59 0.8 0.6
BG (mg/dL) 30–90 26 38 27 29
Serum ketones Negative 3+ 3+ 3+ 3+
NH3 (μg/dL) 90–150 475 634 603 650
Blood pH 7.35–7.45 7.29 7.29 7.09 7.28
AG (mmol/L) 10–14 20.2 22.4 32.2 24.0
Glycine (μM) 110–240 633.7 486 566 552.3
UOA analysis Negative Increased Increased Increased Increased 
excretion of excretion of excretion of excretion of
methylmalonic methylmalonic methylmalonic methylmalonic 
acid acid acid acid
MCM activity* < 0.05 < 0.05 < 0.05 < 0.05
MMA type mut0 mut0 mut0 mut0
DNA analysis c.323G > A, c.1280G > A, c.1280G > A, c.982C > T,
c.1741C > T homozygote c754_755insA homozygote
*The activity of methylmalonic CoA mutase (MCM) of the 4 neonatal patients with MMA was less than 0.05 nmol/min/mg protein vs. the normal control value
of 3.8 nmol/min/mg protein (normal value = 1.7–12.6 nmol/min/mg protein). GA = gestational age at birth; BW = birth weight; C3 = propionylcarnitine; 
C3/C2 = propionylcarnitine/acetylcarnitine ratio; WBC = white blood cell count; Hb = hemoglobin; PLT = platelet count; ALT = alanine transaminase; AST =
aspartate transaminase; BUN = blood urea nitrogen; Cr = creatinine; BG = blood glucose; AG = anion gap (which is [NaCl] − [Cl−] − [HCO3−]); UOA = urine 
organic acid.
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and elevated C3/C2 ratio (0.77) were detected by
MS/MS newborn screening. The patient was imme-
diately referred to our hospital for confirmatory testing
and management.
The results of the laboratory investigations per-
formed on admission are presented in Table 1, and
mut0 type MMA was the diagnosis. Of note, this pa-
tient received conventional therapy with hemodialysis,
which was different from patients 1, 2 and 3. His serum
ammonia level fell (from 650 μg/dL to 73 μg/dL) and
metabolic acidosis was corrected (pH, from 7.28 to
7.36; anion gap, from 24.0mmol/L to 14.4mmol/L)
in 25 hours. GH therapy was also immediately pre-
scribed on admission, and his weight subsequently
showed significant increases, in contrast to that of
patient 1 during the 1st month of admission (Figure 1),
and no skin erosions were found.
The 4 neonatal patients with mut0 type MMA were
identified through MS/MS newborn screening for
elevated C3 levels. Conventional therapy included
dietary management (with the special formula XMTVI
Analog™, a methionine-, threonine-, valine-free and
isoleucine-low powdered infant formula, from SHS,
Liverpool, Merseyside, UK), L-carnitine supplementa-
tion (100 mg/kg/day), and oral antibiotics (metron-
idazole, 20mg/kg/day). GH therapy, 0.6IU/kg/week
subcutaneously (Genotropin®; Pfizer, New York, NY,
USA) was prescribed for patient 1 after 1 month of
admission (on the 31st day of admission), and was
prescribed at the same dose for patients 2, 3 and 4 on
the 1st day of admission. For each patient, an informed
written consent was signed by at least 1 parent. C3 level
was analyzed by MS/MS at the Chinese Foundation
of Health every day.
Results
For patient 1, his weight showed an increase of 834 g
in the 2nd month and 970 g in the 3rd month of admis-
sion, and the skin erosions gradually improved after
GH therapy. For patients 2, 3 and 4, their weights
showed significant increases in the 1st month of admis-
sion (817 g, 701 g and 752 g, respectively), and they
did not experience any deterioration in their condi-
tion, in contrast to what was observed in patient 1.
The lengths of hospital stay for patients 1, 2, 3 and 4
were 81 days, 37 days, 35 days and 34 days, respec-
tively, and their weights at discharge were 4,650 g,
3,827 g, 3,391 g and 3,543 g, respectively. Serum lev-
els of C3 gradually decreased in patients 1 and 2; how-
ever, elevated serum levels of C3 with fluctuations
were found in patients 3 and 4 (Figure 2).
Discussion
The management of mut0 type MMA remains dif-
ficult. With the conventional therapy of diet control,
L-carnitine supplementation and oral antibiotics,
mortality is high and long-term complications are
common.1 Poor growth, one of the most common
complications in patients with MMA, may be caused
by both chronic illness and severely restricted protein
diets.10,11 Many patients with MMA are less than 3
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Figure 1. Effects of growth hormone (GH) therapy on the weight gain of the 4 neonatal patients with methylmalonic acidemia. GH ther-
apy was prescribed for patient 1 after 1 month of admission, but was immediately prescribed for patients 2, 3 and 4 on the 1st day of
admission. The arrows indicate the 1st day of GH therapy.
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Figure 2. Effects of growth hormone (GH) therapy on the serum levels of propionylcarnitine (C3) in the 4 neonatal patients with methyl-
malonic acidemia. GH therapy was prescribed for patient 1 after 1 month of admission, but was immediately prescribed for patients 2,
3 and 4 on the 1st day of admission. The arrows indicate the 1st day of GH therapy.
standard deviations below the norm for both length
and weight.9 Some children had documented GH defi-
ciency ascribed to brain damage, metabolic or nutri-
tional perturbation.9 Therefore, GH deficiency may
be an etiologic factor in the deteriorating condition
seen in patients with MMA.9,10 Clinically, GH, due to
its anabolic effect, has been shown to decrease whole-
body catabolism, increase protein synthesis, accelerate
wound healing, reverse growth arrest, and reduce 
the length of hospital stay in severely burned chil-
dren.12–14 Based on this background, GH therapy
appears to be an important alternative for patients
with MMA.
The clinical course of patient 1, initially managed
with conventional therapy, was complicated with poor
feeding, poor growth, and intractable skin erosions
despite aggressive management. After 1 month of
poor response, GH therapy was prescribed, and sub-
sequently, his clinical condition was much improved.
In contrast, patients 2, 3 and 4 received GH therapy
immediately after admission, and subsequently, their
condition did not deteriorate, which is in sharp con-
trast to the course of patient 1. The improvement in
the clinical condition of the neonatal patients with
MMA confirmed our thoughts on the effectiveness of
GH therapy.
Elevated serum levels of C3 were persistently found
after GH therapy in patients 3 and 4. The metabolic
effects of GH therapy on reducing serum C3 levels
seem to be indeterminate, although decreased serum
levels of C3 were gradually found in patients 1 and 2.
Notably, both patients 3 and 4 demonstrated much
clinical improvement after GH therapy despite per-
sistently elevated serum C3 levels. Theoretically, higher
serum levels of C3 indicate more severe illness. How-
ever, our clinical findings seem to show that elevated
serum C3 levels are unrelated to the clinical manifes-
tations of patients with MMA. Thus, the relationship
between serum C3 level and the clinical manifesta-
tions of MMA remains to be determined.
Liver transplantation is considered to increase
metabolic homeostasis and protect against metabolic
decompensation in patients with MMA. It can pro-
vide an improvement in quality of life due to the mit-
igation of protein restriction, decreasing frequency of
acute decompensation, and alleviation of the state of
the disease.15
Successful liver transplantation has been reported in
infants with a median age of 7.4 months and median
weight of 5.8 kg.16 Growth improvement of patients
with MMA resulted in the clinical benefit of these
patients being able to undergo liver transplantation 
at an earlier age. Patients 1, 2 and 3 have undergone
liver transplantation, and are currently doing well.
Our clinical findings suggest that GH therapy has
potentially beneficial effects in neonatal patients with
MMA, and we hope that our experience can provide
some preliminary data so that more research can be
focused on GH therapy in patients with MMA. Never-
theless, determining the optimal doses of GH therapy
and the long-term prognosis for those with poor
growth will require extensively controlled studies.
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